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Background: The aim of this study was to develop a 48-h mortality risk score, which included morphol-
ogy data, for patients with ruptured abdominal aortic aneurysm presenting to an emergency department,
and to assess its predictive accuracy and clinical effectiveness in triaging patients to immediate aneurysm
repair, transfer or palliative care.
Methods: Data from patients in the IMPROVE (Immediate Management of the Patient With Ruptured
Aneurysm: Open Versus Endovascular Repair) randomized trial were used to develop the risk score.
Variables considered included age, sex, haemodynamic markers and aortic morphology. Backwards
selection was used to identify relevant predictors. Predictive performance was assessed using calibration
plots and the C-statistic. Validation of the newly developed and other previously published scores was
conducted in four external populations. The net benefit of treating patients based on a risk threshold
compared with treating none was quantified.
Results: Data from 536 patients in the IMPROVE trial were included. The final variables retained were
age, sex, haemoglobin level, serum creatinine level, systolic BP, aortic neck length and angle, and acute
myocardial ischaemia. The discrimination of the score for 48-h mortality in the IMPROVE data was
reasonable (C-statistic 0⋅710, 95 per cent c.i. 0⋅659 to 0⋅760), but varied in external populations (from
0⋅652 to 0⋅761). The new score outperformed other published risk scores in some, but not all, populations.
An 8 (95 per cent c.i. 5 to 11) per cent improvement in the C-statistic was estimated compared with using
age alone.
Conclusion: The assessed risk scores did not have sufficient accuracy to enable potentially life-saving
decisions to be made regarding intervention. Focus should therefore shift to offering repair to more
patients and reducing non-intervention rates, while respecting the wishes of the patient and family.
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Introduction
In theUK, themortality rate from ruptured abdominal aor-
tic aneurysm (rAAA) is higher than in the USA, possibly
because non-intervention rates are higher1. Patients pre-
senting to emergency departments with suspected rAAA
require rapid triaging, with a decision whether to provide
immediate aneurysm repair (or immediate transfer to a spe-
cialist centre for repair), or palliative care in those for whom
aneurysm repair may be futile. To help such critical deci-
sions, guidelines for transfer have been developed2,3 and a
number of risk scores have been published to predict post-
operative (usually 30-day) mortality4–7. The majority of
deaths actually occur within the first 48 h8. Many of these
risk scores are based on simple haemodynamic parameters,
yet their predictive ability has been shown to vary when
applied to other populations9,10. One possible reason is that
a risk score performs better on the data from which it was
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derived than in independent data sources; this is especially
true for small studies that considered a large number of
potential predictors11.
To date, risk scores have not incorporated assessments
of aortic morphology. Today these are rapidly available
from emergency CT and may provide critical information
regarding the complexity of any endovascular aneurysm
repair (EVAR) or open repair to be undertaken, as well
as predicting postoperative mortality12,13. The IMPROVE
randomized trial (ISRCTN 48334791)8 of patients with an
in-hospital clinical diagnosis of rAAA recorded a number of
preoperative morphological variables from CT images in
86 per cent of their patients with confirmed rupture. This
trial, therefore, presents an opportunity to assess the value
of adding morphological variables to an rAAA risk score.
The aims of this study were twofold; first, to develop
a novel, point-of-care, risk score for patients presenting
with an rAAA based on the IMPROVE trial data set,
incorporating both physiological and imaging data that
are immediately available in the emergency department;
and, second, to evaluate the newly developed risk score
alongside previously published scores in four independent
external data sets. The external data sources considered
were the AJAX (Amsterdam Acute Aneurysm Trial)14 and
ECAR (Endovasculaire ou Chirurgie dans les Anevrysmes
aorto-iliaques Rompus)15 RCTs, and the Amsterdam area16
and Stockholm area (STAR)17 population-based cohorts
of all rAAA repairs. The previously published risk scores
evaluated were the Vascular Study Group of New England
(VSGNE) score4, the Hardman index5 and the Vancouver
rAAA risk score6, chosen because they are simple to use in
an emergency department.
Attention was focused on predicting 48-h mortality
rather than in-hospital or 30-day mortality because the
highest death rate following repair is in the first 48 h.
Established risk scores have generally been derived using
either in-hospital or 30-day mortality as an outcome, usu-
ally following open repair, and are therefore sensitive to
changes and improvements in critical care; they may also
be sensitive to the increasing use of EVAR for emergency
abdominal aortic aneurysm (AAA) repair.
Methods
Data from the IMPROVE RCT were used to develop
the new score, excluding patients with a final diagno-
sis other than rAAA (incidental or symptomatic AAAs
were excluded); patients with an aortoiliac rupture were
included. All these patients who had CT were considered
in the risk score, regardless of whether aneurysm repair was
started.
External validation of the risk score was conducted in
patients from the AJAX and ECAR randomized trials. The
inclusion criteria for randomization in these twoRCTs, and
hence the patient populations, were more selective than
those in the IMPROVE trial. The IMPROVE trial ran-
domized patients with a clinical diagnosis of rAAA, before
confirmation of either rupture or suitability for EVAR,
and patients did not have to be haemodynamically stable.
The AJAX and ECAR trials required that patients had CT
before randomization to confirm an AAA with acute haem-
orrhage outside the aortic wall, for the patient to be suit-
able for both EVAR and open repair, and for patients to
be haemodynamically stable on arrival. External validation
was undertaken using the wider Amsterdam cohort, which
comprised patients who had rAAA repair but were unsuit-
able for randomization in the AJAX trial, as well as a large
observational cohort of all patients admitted to hospital
with rAAA in the Stockholm area (STAR cohort).
Measurements and outcomes
The outcome was death within 48 h of randomization, or
within 48 h of presentation for the Amsterdam and STAR
cohorts. Management included either open repair, EVAR
or no repair. In secondary analyses, the 48-h risk score
was also assessed for its ability to predict 30-day mortality
reliably.
A set of variables was predefined for potential inclusion
in the risk score, based on data available from the three
rAAA trials (IMPROVE, AJAX and ECAR). These vari-
ables included: age, sex, admission systolic BP, additional
admission variables for calculation of the Hardman index
(haemoglobin level, serum creatinine level, acute myocar-
dial ischaemia on ECG and loss of consciousness), and four
basic morphological features of the aneurysm as measured
fromCT images, chosen because they are required to assess
the feasibility of EVAR and are relatively easy tomeasure in
a time-critical situation (maximum aortic diameter, aortic
neck diameter, aortic neck length and proximal neck angle).
None of the validation data sets provided data regarding
the volume of intravenous fluids administered. Neverthe-
less, this variable was also assessed for its predictive abil-
ity when developing the model using the IMPROVE data.
The IMPROVE data were recorded from the trial centres,
which was not necessarily the hospital to which the patient
presented.
Statistical analysis
Any non-linear relationship between each of the nine
continuous candidate predictors (age, haemoglobin level,
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1135–1144
on behalf of BJS Society Ltd.
Mortality risk score for patients with ruptured abdominal aortic aneurysm 1137
serum creatinine level, admission systolic BP, volume of
intravenous fluids administered, maximum aortic dia-
meter, aortic neck diameter, aortic neck length, proximal
aortic neck angle) and 48-h mortality was first assessed
using fractional polynomials (FPs)18 in a logistic model
based on complete data (Appendix S1, supporting infor-
mation). The shape of association was plotted for each
predictor using the final chosen FP to check biological
plausibility.
To deal with missing data for the predictors, multi-
ple imputation was carried out (Appendix S1, supporting
information). A multivariable logistic regression model
was then chosen using a backwards selection procedure,
whereby all candidate predictors were initially included
using their chosen FP transformation, and variables
were dropped progressively from the model if their P
value was 0⋅157 or higher. The pooled coefficients of
the selected variables across the multiply imputed data
sets were used to define the risk score. For ease of use,
a nomogram19 was constructed based on the derived
risk score.
The predicted probabilities of 48-h mortality were
assessed in terms of calibration and discrimination. Cali-
bration was assessed by plotting observed versus predicted
risks within deciles of predicted risk, and reporting the esti-
mated calibration slope from a logistic regression model
with the risk score as the predictor20. Discrimination was
assessed by calculating the C-statistic (the area under the
receiver operating characteristic (ROC) curve).
Internal validation (within the IMPROVE data set) was
conducted using tenfold cross-validation to avoid over-
optimistic estimates of predictive performance caused by
overfitting (Appendix S1, supporting information). External
validation was conducted using data from the AJAX and
ECAR trials, and the Amsterdam and STAR cohorts, to
give an assessment of how well the derived risk score
applied in other populations.
The predictive performance of other published risk
scores4–6 was assessed in each data source. Preoperative
cardiac arrest was recorded only in the IMPROVE data
set and so was dropped from the published risk scores in
data in which it was missing. Furthermore, the VSGNE
score included the use of a suprarenal clamp as a predictor,
which was not specifically recorded in these data sets,
and so a proxy (aortic neck length less than 10mm) was
used instead. The derivation of each score is provided in
Table S1 (supporting information).
The clinical value of any particular rAAA risk score
depends on the ability to make better decisions with a
model than without21. Following methodology developed
by Vickers and Elkin22, the net benefit of treating patients
at different risk cut-offs versus treating none was quantified
and the value of an rAAA risk score assessed. The net
benefit is based on an assumed benefit to risk trade-off;
for example, a surgeon treating patients with a mortality
probability of 98 per cent or less quantifies the consequence
of not operating when it would have been of benefit as 98 to
2, that is 49 times worse than the consequence of operating
unnecessarily20.
Results
A total of 536 patients from IMPROVE with a final diag-
nosis of rAAA were included, of whom 135 (25⋅2 per cent)
died within 48 h of randomization. Some 320 patients com-
menced open repair, 182 started EVAR and a further 34 did
not have an operation as they died before reaching thea-
tre. A total of 327 patients (61⋅0 per cent) from IMPROVE
arrived from another hospital; the 48-h mortality rate in
these patients was 24⋅2 per cent, similar to that among
patients who arrived directly. There were 113 and 107
patients in the AJAX andECAR trials respectively, of whom
17 (15⋅0 per cent) and 15 (14⋅0 per cent) died within 48 h
of randomization. Patients in IMPROVE were a mean of
2 years older, had larger aneurysms, and a greater propor-
tion of women were recruited (Table 1). In the Amsterdam
cohort, 114 of 402 patients (28⋅4 per cent) died within
48 h, whereas the mortality rate was much higher in the
STAR cohort (107 of 284; 37⋅7 per cent), in part because
patients were a mean of 4 years older, and one-quarter did
not receive any aneurysm repair. Patients in the STAR
cohort also had a lower mean systolic BP on admission, and
a higher proportion had lost consciousness before arrival
at the operating theatre. The mortality rate at 30 days was
40–60 per cent higher than at 48 h; the in-hospital mor-
tality rate was similar to the 30-day mortality rate in all
cohorts.
Risk score development
Unadjusted odds ratios for each candidate variable esti-
mated in the IMPROVE trial after multiple imputation
are shown in Table S2 (supporting information). Most can-
didate predictors correlated with the outcome. FP mod-
elling indicated a cubic effect of age, an inverse-squared
effect of admission systolic BP and a log-transformed
effect of neck length on the log-odds of mortality (Fig. S1,
supporting information). Following backwards variable
selection, the final variables retained in the multivariable
prediction model were: age, sex, haemoglobin level on
admission, serum creatinine level on admission, systolic
BP on admission, aortic neck length, aortic neck angle,
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Table 1 Descriptive statistics for the candidate predictors for the three RCTs and two cohorts
IMPROVE RCT AJAX RCT ECAR RCT Amsterdam cohort STAR cohort
n
No. with
event* n
No. with
event* n
No. with
event* n
No. with
event* n
No. with
event*
Death within 48 h 536 135 (25⋅2) 113 17 (15⋅0) 107 15 (14⋅0) 402 114 (28⋅3) 284 107 (37⋅7)
Death within 30days 536 206 (38⋅4) 113 27 (23⋅9) 105 22 (21⋅0) 401 171 (42⋅6) 284 147 (51⋅8)
Death before primary
hospital discharge
536 211 (39⋅4) 113 32 (28⋅3) 104 29 (27⋅9) 402 179 (44⋅5) 284 149 (52⋅5)
Operation commenced
EVAR
Open aneurysm repair
No operation (palliated)
536
182 (34⋅0)
320 (59⋅7)
34 (6⋅3)
113
55 (48⋅7)
58 (51⋅3)
0 (0)
107
56 (52⋅3)
50 (46⋅7)
1 (0⋅9)
402
15 (3⋅7)
329 (81⋅8)
58 (14⋅4)
279
59 (21⋅1)
147 (52⋅7)
73 (26⋅2)
Age (years)† 536 76(8) 113 74(9) 107 74(11) 402 75(9) 284 79(9)
Male sex 536 424 (79⋅1) 113 97 (85⋅8) 107 97 (90⋅7) 402 303 (75⋅4) 284 215 (75⋅7)
Admission haemoglobin
(g/dl)†
530 11⋅1(2⋅4) 113 11⋅5(2⋅3) 107 10⋅6(2⋅3) 387 11⋅0(2⋅6) 273 11⋅1(2⋅3)
Admission creatinine
(μmol/l)‡
524 118
(95–153)
107 106
(91–142)
105 114
(91–136)
366 110
(89–139)
268 117
(90–140)
Admission systolic BP
(mmHg)†
526 108(32) 110 120(40) 104 108(30) 328 111(36) 283 104(39)
Volume of i.v. fluids given
before arrival in theatre
(litres)†
391 1⋅06(1⋅13) – – – – – – – –
Maximum aneurysm
diameter (mm)†
460 86(17) 92 76(16) 106 77(20) – – 192 81(19)
Aneurysm neck diameter
(mm)†
390 25(4) 92 26(4) 106 24(5) – – 192 29(11)
Neck length (mm)† 435 23(17) 92 27(13) 101 25(14) 180 17(14) 192 18(18)
Proximal neck angle (∘)† 432 33(20) 92 39(21) 96 34(26) 180 37(23) 192 23(16)
Acute myocardial
ischaemia detected on
ECG
495 38 (7⋅7) 65 12 (18) 107 4 (3⋅7) 128 29 (22⋅7) 139 60 (43⋅2)
Loss of consciousness 512 47 (9⋅2) 113 13 (11⋅5) 107 12 (11⋅2) – – 284 68 (23⋅9)
Preoperative cardiac arrest 536 8 (1⋅5) – – – – – – – –
*With percentages in parentheses unless indicated otherwise; values are †mean(s.d.) and ‡median (i.q.r.). EVAR, endovascular aneurysm repair; i.v.,
intravenous.
and acute myocardial ischaemia on ECG. Coefficients
based on transformations of these variables are shown
in Table 2, and these define the IMPROVE risk score.
A nomogram to allow simple use of the score is pre-
sented in Fig. 1. A shorter neck length was strongly asso-
ciated with higher 48-h mortality risk (P< 0⋅001), whereas
a smaller neck angle was weakly associated with higher
risk (P= 0⋅113). In a post hoc analysis, among patients
who had an operation, the inverse relationship with neck
angle was apparent only in those who received open
repair.
Calibration and discrimination
Calibration plots are shown in Fig. 2 for the IMPROVE
score applied to the IMPROVE data. The score was gen-
erally well calibrated, particularly for individuals at lower
risk. The calibration slope was estimated as 1⋅08 (95 per
cent c.i. 0⋅83 to 1⋅32), compatible with a value of 1, indi-
cating good calibration.
Table 2 IMPROVE score coefficients from multivariable logistic
regression
β P
Intercept –1⋅1041 (0⋅7750)(
Age−50
5
)3
(years) 0⋅0028 (0⋅0008) 0⋅001
Haemoglobin (g/dl) –0⋅0933 (0⋅0524) 0⋅075(
Creatinine
100
)
(μmol/l) 0⋅4391 (0⋅1615) 0⋅007
(
Systolic BP+1
100
)−2
(mmHg) 0⋅4743 (0⋅1350) < 0⋅001
log
(
Neck length+1
10
)
(mm) –0⋅3450 (0⋅0912) < 0⋅001(
Neck angle+1
10
)
(∘) –0⋅0973 (0⋅0614) 0⋅113
Sex (M) –0⋅4954 (0⋅2652) 0⋅062
Acute myocardial ischaemia 1⋅0429 (0⋅3684) 0⋅005
Values in parentheses are standard errors.
The discriminative ability of the IMPROVE score was
reasonable, but not exceptional, with a C-statistic of 0⋅710
when assessed in the IMPROVE trial (Table 3). When vali-
dated on the four external data sets, the predictive ability of
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1135–1144
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Acute myocardial ischaemia
Sex
No Yes
Male Female
45 30 20 10 56090
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48-h mortality risk (%)
Fig. 1 Nomogram showing the IMPROVE risk score for 48-h mortality for patients with ruptured abdominal aortic aneurysm. To use
this nomogram, each of the patient’s characteristics is assessed and the associated score read off (upper part). The total score is obtained
by summing the scores from each of the individual characteristics, and the predicted 48-h mortality risk can then be obtained (lower
part)
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Fig. 2 Calibration plot for the IMPROVE risk score in the
IMPROVE data set
the IMPROVE score was comparable to the performance
seen in the IMPROVE trial, with C-statistic values ranging
from 0⋅652 to 0⋅761.
There was no evidence that the IMPROVE risk score had
better discriminative ability among patients who arrived
directly compared with those transferred from another
hospital (C-index 0⋅726 versus 0⋅697; P= 0⋅579).
Comparison with other published risk scores
In terms of discrimination, the IMPROVE score outper-
formed other published risk scores in the IMPROVE trial
data (VSGNE, P= 0⋅010; Hardman, P= 0⋅013; Vancou-
ver, P= 0⋅013) and in the Amsterdam cohort (VSGNE,
P< 0⋅001; Hardman, P< 0⋅001; Vancouver, P< 0⋅001). All
risk scores were comparable in the AJAX and ECAR tri-
als, and in the STAR cohort. There was heterogeneity in
the performance of each risk score when applied to differ-
ent populations. Overall performance of each risk score in
comparison to the predictive discrimination of using age
alone is shown in Fig. 3, with the mean C-statistic increase
pooled across cohorts and weighted by the study-specific
number of events. The change in C-statistic was high-
est when the IMPROVE score was used, although the
mean increase was still rather limited (change in C-statistic
0⋅08, 95 per cent c.i. 0⋅05 to 0⋅11). The performances
of the risk scores in the STAR cohort were particularly
modest, with only the Vancouver score showing a sig-
nificant improvement in the C-statistic compared with
age alone.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1135–1144
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Table 3 Estimated C-statistics for the IMPROVE risk score and other published risk scores for predicting 48-h mortality, when applied
to five different populations
IMPROVE RCT (n=536) AJAX RCT (n=113) ECAR RCT (n=107) Amsterdam cohort (n=402) STAR cohort (n= 284)
IMPROVE score 0⋅710 (0⋅659, 0⋅760)* 0⋅680 (0⋅565, 0⋅796) 0⋅719 (0⋅570, 0⋅867) 0⋅761 (0⋅713, 0⋅810) 0⋅652 (0⋅586, 0⋅719)
VSGNE score 0⋅638 (0⋅585, 0⋅691) 0⋅634 (0⋅509, 0⋅764)† 0⋅674 (0⋅543, 0⋅805)† 0⋅640 (0⋅582, 0⋅697)‡ 0⋅655 (0⋅590, 0⋅720)†
Hardman index 0⋅648 (0⋅597, 0⋅698) 0⋅754 (0⋅658, 0⋅850)† 0⋅731 (0⋅597, 0⋅865)† 0⋅675 (0⋅618, 0⋅732)† 0⋅606 (0⋅537, 0⋅674)†
Vancouver score 0⋅635 (0⋅579, 0⋅690) 0⋅609 (0⋅453, 0⋅764)† 0⋅725 (0⋅591, 0⋅860)† 0⋅654 (0⋅592, 0⋅715)‡ 0⋅702 (0⋅638, 0⋅766)†
Values in parentheses are 95 per cent confidence intervals. *Cross-validated C-statistic (optimism-corrected); †excluding preoperative cardiac arrest,
‡excluding preoperative cardiac arrest and loss of consciousness. VSGNE, Vascular Study Group of New England.
IMPROVE score
IMPROVE
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ECAR
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Fig. 3 Change in C-statistic for four ruptured abdominal aortic aneurysm risk scores compared with the reference score using age alone
as a risk factor. The change in C-statistic was calculated in each cohort and for each risk score compared with using age alone. The
changes were then pooled across cohorts. Changes in C-statistic are shown with 95 per cent confidence intervals. The Vancouver score
in the Amsterdam cohort contained only the effect of age because cardiac arrest and loss of consciousness were not available; therefore,
no comparisons with an age-alone model could be made
Performance of the risk scores in predicting 30-day
and in-hospital mortality
The four different risk scores were also assessed for their
ability to predict 30-day and (primary) in-hospitalmortality
(Tables S3 and S4, supporting information). The predictive
performance of the IMPROVE score was similar to that
for prediction of 48-h mortality; in comparison with the
48-h prediction, the C-statistic increased in some studies
and decreased in others for both 30-day and in-hospital
mortality. For the three previously published risk scores
(VSGNE, Hardman and Vancouver) the C-statistics for
30-day and in-hospital mortality were often higher than the
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1135–1144
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Fig. 4 Decision curve showing the benefit of the IMPROVE risk
score in helping make treatment decisions. The benefit to risk
trade-off inferred by a surgeon’s chosen threshold probability of
operating on a patient is shown on the x-axis. For example, a
surgeon who would treat patients with a mortality probability of
98 per cent or less quantifies the consequence of not operating
when it would have been of benefit as 98 to 2, that is 49 times
worse than the consequence of operating unnecessarily. The
dotted line shows the net benefit (relative to treating no one) of
treating everyone as a function of the benefit to risk trade-off
(chosen threshold). The dashed line shows the net benefit
(relative to treating no one) of treating only those with a
mortality risk below the chosen threshold
48-h C-statistic values in all studies except for the ECAR
randomized trial, underlining the fact that these scores
were developed using 30-day or in-hospital mortality as the
outcome.
Decision curve analysis
The net benefit of using the IMPROVE score at a range
of possible threshold probabilities to treat patients, in con-
trast to treating no one, is shown in Fig. 4. The net ben-
efit of treating everyone is higher than that of treating no
one when the consequences of not operating are deemed
much worse than the consequences of operating unnec-
essarily (the threshold probability is high). At a threshold
probability of 1⋅0, surgeons would value an operation as
infinitely better than no operation, and so the treat-all sce-
nario gives the highest net benefit. If treatment decisions
are based on the IMPROVE rAAA risk score, then the net
benefit is almost identical to that of treating everyone for
risk thresholds above 50 per cent. The benefit of using an
rAAA risk score in clinical decision-making only becomes
apparent for surgeons who would only treat patients with
a predicted 48-h mortality risk of 40 per cent or less. A
higher predicted risk threshold of 90 per cent would cor-
rectly identify for surgery all 401 survivors in IMPROVE,
but would also identify for surgery 133 of 135 patients (98⋅5
per cent) who died within 48 h.
Discussion
The value of the rAAA risk scores assessed here when
applied to different populations was poor. The IMPROVE
risk score was the only one to focus on 48-hmortality, more
likely to be related to bleeding than multiple organ failure,
and the only score to include morphological parameters.
However, like all previous risk scores, it was derived from
patients admitted to vascular surgery units.Moreover, it did
not perform substantially better than older scores, which
were based on demographic and haemodynamic variables
only and focused on 30-day mortality. As any risk score
should be generalizable, the Stockholm area cohort was
particularly important, because it included patients with
rAAA admitted to hospitals in the Stockholm area, not just
those admitted to the vascular centres or who underwent
repair.
In general, all available rAAA risk scores do not have suf-
ficient accuracy to enable surgeons to use them to make
life-or-death decisions regarding surgery, as highlighted in
the decision curve analyses. This conclusion is in agree-
ment with a recent study10 that evaluated five different
scoring systems for 30-daymortality on an historical cohort
of Dutch patients with rAAA presenting to two vascular
centres (outside the Amsterdam area). This study evalu-
ated the Vancouver and Hardman scores, together with the
Glasgow and Edinburgh scores and the newly developed
Dutch Aneurysm Score23, with C-statistic values ranging
from 0⋅59 to 0⋅72. Vos and colleagues10 also concluded that
almost perfect prediction is needed to withhold interven-
tion, and no current scoring system is capable of that. Nev-
ertheless, operative mortality risk is not the only important
consideration, and factors such as postoperative quality of
life must also play a major role in the decision-making pro-
cess.
The IMPROVE risk score has shown that there are some
important predictors of survival to 48 h after emergency
admission, including aneurysm neck length, which com-
plicates emergency surgical repair by influencing the fea-
sibility of aortic grafting. Some of these predictors were
found to have a non-linear relationship with mortality. An
inverse relationship between aortic neck angle and risk
was identified, but this was of marginal significance in the
multivariable model (P= 0⋅113), and in post hoc analysis
was evident only in those who had open repair. This find-
ing may be explained by easier proximal clamping in open
repair when the neck is angulated. The inverse relationship
between neck angle and mortality is at odds with previous
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observations24, so this finding should be treated with cau-
tion. The IMPROVE score performed reasonably among
patients in the IMPROVE trial, and outperformed other
published risk scores in validation on some, but not all,
external patient populations. However, some of the vari-
ables used to derive the published risk scores were not avail-
able in the data sets evaluated here, which may have led to
the reduced risk score that was evaluated being suboptimal.
The findings reported here suggest that further research
to assess the role of risk scores in the transfer of patients,
from centres without emergency vascular cover to special-
ist vascular centres, would not be fruitful. The inability of
risk scores to predict outcomes following emergency sur-
gical repair, with sufficient accuracy for individual clinical
decision-making, indicates that any risk score should be
used only for comparing different populations of patients
with rAAA or risk-adjusting such data. Which risk score to
use for comparing the patients in different studies is likely
to be a matter for debate, but a score that includes some
morphological parameters is a strong contender.
There are a number of reasons why the mortality risk of
patients with rAAA cannot be predicted accurately. First,
there is heterogeneity in treatment and non-intervention
rates, which could result in differences in risk score per-
formance across populations. Second, if the decision to
palliate is based on external factors, the effect of the risk
score could be diluted. A limitation of all derived rAAA
risk scores is that the outcomes of those palliated had they
undergone repair instead will never be known, and the
remaining patients who do undergo repair are therefore
already preselected. To provide good predictive discrimina-
tion, variation in risk factors in the population needs to be
high, and preselection may influence this. The IMPROVE
risk score was developed in patients deemed suitable for
rAAA repair at presentation and may therefore be biased
towards more physically fit patients. Inclusion and exclu-
sion criteria were applied in all the cohorts studied, except
for the STAR cohort, which was the only data set that
included all patients with rAAA in the population who were
admitted to hospital. None of the risk scores performed
well in this cohort.
Because the mortality risk of rAAA repair cannot be
predicted with sufficient accuracy, the focus should shift
to offering repair to more patients and on reducing
non-intervention rates for rAAA repair, which may be too
high in England1. It is of interest that, when a Delphi
consensus approach was used to formulate guidelines for
the transfer of patients to specialist vascular centres, car-
diac arrest in the same admission was the only condition
with complete agreement that the patients should not be
transferred2. Yet, there is some evidence that a few patients
(14 per cent) may survive emergency repair of rAAA even
after a preoperative cardiac arrest25, although the quality
of life in survivors has not been documented. In such
life-or-death situations, perhaps it is just not ethical to
consider using risk scores to withhold treatment, and the
focus should remain on ensuring that the wishes of the
patient and their family are respected.
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Editor’s comments
Is this the definitive word on preoperative risk scores ruptured AAA? In my opinion, yes. This elegant and
comprehensive research shows convincingly that in this dire circumstance the computer cannot assist and decisions
must be made by surgeons, taking into account their patient’s best interests. Perhaps reassuringly, artificial intelligence
may not conquer all aspects of medicine and surgery.
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